United States FDA Bans FD&C Red No. 3 (Erythrosine): What Food, Beverage, And Pharma Companies Need To Know

Introduction: A Landmark Shift in U.S. Color Additive Regulation

The FDA ban on FD&C Red No. 3 (erythrosine) marks a pivotal moment in U.S. food additive regulation, pharmaceutical excipient compliance, and regulatory toxicology policy.

On January 15, 2025, following a federal court order, the U.S. Food and Drug Administration (FDA) officially revoked authorization for erythrosine in:

• Food products 
• Beverages 
• Ingested pharmaceutical products 

This decision has triggered strict regulatory compliance deadlines and significant industry-wide reformulation challenges, making it one of the most impactful FDA color additive regulatory updates in recent years.

Key Compliance Deadlines for Industry

After these deadlines, any product containing erythrosine will be classified as adulterated under the FD&C Act, exposing companies to:

• Product recalls 
• Import/export restrictions 
• Regulatory enforcement actions 
• Market withdrawal risks 

The Delaney Clause: Legal Driver Behind the Ban

The ban is rooted in the Delaney Clause, a hazard-based regulatory provision introduced under:

• 1958 Food Additives Amendment 
• 1960 Color Additives Amendment 

Key Principle of the Delaney Clause

• Any additive shown to cause cancer in humans or animals must be banned 
• No consideration of: 
  • Exposure level 
  • Dose-response relationship 
  • Human relevance 

Conflict with Modern Regulatory Science

Today’s risk-based toxicology framework evaluates:

Risk = Hazard × Exposure × Potency

However, the Delaney Clause enforces a zero-risk legal standard, creating a disconnect between:

• Scientific evidence (risk-based safety) 
• Legal enforcement (hazard-based prohibition) 

Why FD&C Red No. 3 (Erythrosine) Was Banned

Erythrosine is a synthetic xanthene dye widely used for decades in:

• Confectionery products 
• Processed foods 
• Pharmaceutical coatings 

Despite continued approval in Europe and Canada, the U.S. ban stems from a 2022 color additive petition citing rodent carcinogenicity studies.

Key Scientific Findings

• Male rats exposed to extremely high doses (~107,000× human intake) developed benign thyroid tumors 
• No tumors observed in: 
  • Female rats 
  • Mice 
  • Other species 
• No evidence of genotoxicity 

Importantly, the FDA stated:

There is no evidence that erythrosine causes cancer in humans

Mechanistic Toxicology: Understanding the Mode of Action

Erythrosine-induced tumors are linked to thyroid hormone disruption in rodents.

Biological Pathway

• Inhibition of 5’-monodeiodinase enzyme 
• Reduced conversion of T4 → T3 
• Lower circulating T3 levels 
• Increased TSH (thyroid-stimulating hormone) 
• Chronic TSH elevation → thyroid cell proliferation → tumors

Critical Insight

• Mechanisms are non-genotoxic and hormone-mediated 
• Observed only in male rats at extreme doses 

Human Relevance: Why the Risk Is Considered Negligible

Scientific consensus indicates rodent thyroid tumors are not predictive of human cancer risk.

Key Physiological Differences

Human Outcome

• Chronic TSH elevation typically leads to goiter, not cancer 
• No epidemiological evidence linking erythrosine to human carcinogenicity 

Regulatory Implications for Industry

The FDA erythrosine ban 2025 highlights a critical regulatory reality:

Legal frameworks can override scientific risk assessments

Key Industry Challenges

• Urgent product reformulation timelines 
• Increased scrutiny for color additive approvals 
• Need for robust toxicology data in submissions 
• Potential for future bans based on hazard criteria 

Strategic Impact

• Surge in demand for natural and alternative colorants 
• Greater regulatory focus on excipient safety in pharmaceuticals 
• Increased investment in regulatory toxicology and risk assessment 

Reformulation Strategy: What Companies Should Do Now

To ensure compliance with FDA color additive regulations, companies should:

Immediate Actions

• Conduct ingredient portfolio audit 
• Identify products containing erythrosine 
• Initiate alternative colorant screening 
• Perform stability and compatibility testing 

Regulatory Actions

• Prepare premarket color additive petitions 
• Develop toxicology and safety dossiers 
• Align with global regulatory frameworks (FDA, EFSA, Health Canada) 

Global Regulatory Landscape: Alignment & Divergence

This divergence creates complexity for global product harmonization and regulatory strategy

Outlook: What This Means for Regulatory Toxicology

The FDA ban on FD&C Red No. 3 signals:

• Continued relevance of hazard-based regulatory policies 
• Increased legal challenges to existing additives 
• Shift toward clean-label and natural alternatives
• Greater emphasis on mechanistic toxicology data 

Maven Regulatory Solutions

At Maven Regulatory Solutions, we bring deep expertise in:

• FDA color additive regulatory strategy 
• Toxicological risk assessment & mechanistic evaluation 
• Premarket submission and petition preparation 
• Global regulatory alignment (FDA, EFSA, Health Canada) 
• Reformulation strategy for food, beverage, and pharmaceutical products 

Navigate FDA Compliance with Confidence

Facing challenges with:

• Erythrosine reformulation deadlines (2027/2028)? 
• FDA color additive compliance strategy? 
• Toxicology data and regulatory submissions? 

Partner with Maven Regulatory Solutions to:

• Ensure end-of-the-end regulatory compliance 
• Develop robust safety and toxicology dossiers 
• Accelerate market-ready reformulation strategies 

Connect with our experts to future-proof your product portfolio and regulatory strategy

FAQ – FDA Ban on FD&C Red No. 3

1. Why did the FDA ban erythrosine?

Due to the Delaney Clause, which mandates banning additives linked to cancer in animal studies.

2. Is erythrosine harmful to humans?

Current evidence shows no significant cancer risk in humans.

3. What happens after 2027/2028 deadlines?

Products containing erythrosine will be considered adulterated and non-compliant.

4. What industries are affected?

• Food & beverage 
• Pharmaceuticals 
• Nutraceuticals 

5. What are alternatives to erythrosine?

Natural and synthetic alternatives must undergo regulatory approval and safety evaluation.

Conclusion

The FDA ban on FD&C Red No. 3 (erythrosine) is more than a regulatory action it is a defining example of how legal frameworks, scientific evidence, and public health policy intersect.

For industry stakeholders, this reinforces the need for:

• Proactive regulatory strategy 
• Strong toxicological evidence 
• Agile reformulation capabilities 

Maven Regulatory Solutions stands ready to support organizations in navigating these complexities with precision, compliance, and confidence.